The experimental drug J147 is something of a modern elixir of life; it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults.
The technological advances taking place in the medical device and equipment field has been astounding and is cause for much anticipation in 2018. It has opened a world of opportunity for those individuals who would like to not only improve their services, but also their business prospects. With so many medical device trade shows out there, Drugdu.com has narrowed it down to 5 not to be missed exhibitions for 2018.
Naidex is Europe's most exciting event dedicated to the disability, independent living and healthcare professional sectors. In the wake of the huge success of the most recent instalment of this esteemed and long-established event, Naidex will return for its 44th year to the Birmingham NEC on the 25th & 26th April 2018.
We would like to invite your participation in the below largest and most prestigous MEDICAL & PHARMACEUTICAL exhibitions in Ho Chi Minh City and Hanoi City (Vietnam):
The 2018 MEDICARE TAIWAN (Taiwan International Medical & Healthcare Exhibition) and SenCARE (Taiwan International Senior Lifestyle and Health Care Show), the biggest medical and healthcare show in Taiwan, will be held from June 21 – 24, 2018, at Taipei World Trade Center Exhibition Hall 1(TWTC).
Novartis announced the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017.
Women who regularly work the night shift in Europe and North America may face a 19 percent higher risk of cancer than those who work during the day, said a study Monday.
Fitbit has invested $6 million in a glucose-monitoring startup called Sano, in what appears to be part of Fitbit’s larger plans to make its fitness devices more valuable for overall health.
he gene-editing technology CRISPR could very well one day rid the world of its most devastating diseases, allowing us to simply edit away the genetic code responsible for an illness. One of the things standing in the way of turning that fantasy into reality, though, is the problem of off-target effects. Now Microsoft is hoping to use artificial intelligence to fix this problem.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.